We use business to fight for social justice

Sustainability Report 2023

A conversation about a new way of doing business

Sergi Ferrer-Salat, president of Ferrer, Mario Rovirosa, CEO of Ferrer, and Matthew McCarthy, former CEO of Ben & Jerry's, talk about purpose, activism, leadership and the future of companies.

The year at a glance

Hitos EN

Hitos EN

Our way of doing business

We are a company that has been looking to do things differently for years; Instead of maximizing shareholder returns, we return a large part of our profits to society and allocate them where they are truly needed. We go beyond compliance and abide by the highest standards of sustainability, ethics and integrity.

Great People

We promote a people-oriented culture, based on trust and responsibility, in which talent thrives. Because we firmly believe that, only through the effort and involvement of our entire human team and the people with whom we collaborate, will we be able to materialize our purpose.

Liveable Planet

At Ferrer we believe that our activity as a pharmaceutical company must create more environmental value than it consumes, involving our value chain to challenge established norms and thus lead the path towards sustainability, making our planet a more liveable place.

Therefore, we promote the preservation of the environment for our own good and that of future generations.

Learn about our environmental objectives achievements by clicking here.

Collective Action

We explore new forms of collaboration to address our society's most critical challenges. We support people in vulnerable situations, through our foundations, we have the involvement of people who work in the company and we collaborate with other entities and organizations that have been leaders in these issues for years.

Our activity

With the aim of providing significant and differential value to people suffering from serious ailments, at Ferrer we are developing a growing focus on two therapeutic areas: pulmonary vascular and interstitial lung diseases and neurological disorders.

Rare or low-prevalence diseases converge in both areas, frequently lacking appropriate or authorized treatments. For this reason, Ferrer's commitment to research and development of treatments in these areas is crucial to improving the lives of affected patients, as well as to efficiently manage health resources.

Sustainability reports from previous years:
 

2019  2020  2021  2022